Treatment With Apremilast in Patients With Psoriatic Arthritis
Status:
Withdrawn
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Apremilast (Otezla®) is a Federal Drug Administration (FDA)-approved treatment for psoriatic
arthritis and psoriasis. Although there are a lot of data demonstrating how apremilast works
in the laboratory, there are very few demonstrating how it works in the actual target organ,
i.e. the skin or synovial (joint) tissue in patients with psoriasis and psoriatic arthritis.
Laboratory data has demonstrated that apremilast decreases inflammatory proteins and
increases anti-inflammatory proteins. However, almost all of these data/studies have been
performed on the blood of patients with psoriasis and psoriatic arthritis, not the skin or
synovial (joint) tissue. These studies that have been performed on the blood of patients with
this condition may, or may not, reflect the true response to therapy in the synovial (joint)
tissue and/or skin.